Abbott raises 2026 EPS guidance, reports pipeline progress across device portfolio

Abbott Laboratories reported second-quarter 2026 results on July 16, 2026, with sales increasing 13.0 percent on a reported basis and 4.8 percent on a comparable basis.¹ The company raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58.¹ It also reaffirmed full-year 2026 comparable sales growth guidance of 6.5% to 7.5%.¹ For the third quarter, Abbott projects adjusted diluted earnings per share of $1.38 to $1.46.¹

On the pipeline side, Abbott said that in April it completed enrollment in its TECTONIC U.S. pivotal trial, designed to evaluate Abbott's investigational Coronary Intravascular Lithotripsy System for treating severe calcification in coronary arteries prior to stent implantation.¹ Also in April, at the Heart Rhythm Society conference, Abbott presented new late-breaking data from four clinical trials that demonstrated strong clinical outcomes across the company's pulsed field ablation and conduction system pacing portfolios.¹

In May, Abbott said it secured CE Mark for Libre Duo, described as the world's first dual glucose-ketone biowearable sensor, which the company said helps optimize diabetes management by detecting rising ketone levels that can lead to diabetic ketoacidosis.¹ Also in May, Abbott completed its submission to the FDA seeking approval for the company's Amulet 360 left atrial appendage device.¹ Separately, the American Cancer Society issued updated colorectal cancer screening guidelines that reaffirmed Cologuard and Cologuard Plus as preferred screening options for adults age 45 and older at average risk.¹

On capital allocation, Abbott said it declared its 410th consecutive quarterly dividend of $0.63 per share on June 12, 2026, payable Aug. 17, 2026, to shareholders of record as of July 15, 2026.¹